Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Atara Biotherapeutics, Inc. (NASDAQ: ATRA).

Full DD Report for ATRA

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATRA)

Atara Biotherapeutics to Present Long-Term Tab-cel(TM) Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association
SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the Company and...
Source: GlobeNewswire
Date: May, 17 2018 09:00
Atara Biotherapeutics: A Gift That Keeps On Giving
All intelligent investing is value investing — acquiring more than you are paying for. - Charlie Munger Atara Biotherapeutics (NASDAQ: ATRA ) was an extremely intriguing growth story back in 2017. Its shareholders have been riding on fortune - garnered since the approval of the ...
Source: SeekingAlpha
Date: May, 17 2018 04:01
Rounds Report: Omeros Rallied Robustly While Stellar FDA Due Diligence To Help Orphan Disease Innovators
Those who keep learning will keep rising in life. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 14, 2018. As usual, we’ll elucidate notable trading analytics for the day, recent insider transactions, and interesting market d...
Source: SeekingAlpha
Date: May, 16 2018 06:38
Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
Source: SeekingAlpha
Date: May, 15 2018 10:33
Biotechs Emerge Unscathed And Ready To Go!
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th...
Source: SeekingAlpha
Date: May, 15 2018 08:28
Rounds Report: Omeros Rallied While Stellar FDA Due Diligence To Help Atara Biotherapeutics
You need a different checklist and different mental models for different companies. I can never make it easy by saying, ‘Here are three things.’ You have to derive it yourself to ingrain it in your head for the rest of your life. - Charlie Munger Trading Analytics Welcome...
Source: SeekingAlpha
Date: May, 13 2018 03:46
Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies
Stock Monitor: Cellectis Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Atara Biotherapeutics, Inc. (NASDAQ: ATRA ) ("Atara"), all you need to do is sign up now by clicking the following link www.active-investors.co...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:30
Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for...
Source: GlobeNewswire
Date: May, 08 2018 07:05
Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases
Entry into genetically engineered T-cells marks next step in Atara’s strategy to advance leadership position in off-the-shelf, allogeneic T-cell immunotherapy SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-th...
Source: GlobeNewswire
Date: May, 08 2018 07:00
Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development
SOUTH SAN FRANCISCO, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced Dietmar P. Berger, M...
Source: GlobeNewswire
Date: May, 07 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1747.1047.9048.0546.35565,043
2017-06-2013.4513.5013.8513.30242,367
2017-06-1912.8013.4513.9512.75308,051
2017-06-1612.2012.7513.4012.15863,129
2017-06-1512.6512.3012.9011.80320,442

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1739,61064,11461.7806Short
2018-08-1637,86574,85450.5851Short
2018-08-1564,18887,45273.3980Short
2018-08-1430,99642,28773.2991Short
2018-08-1327,79531,12189.3127Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATRA.


About Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

Logo for Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ATRA)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 10 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 09 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 02 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: March, 01 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: March, 01 2018

       

       


      Daily Technical Chart for (NASDAQ: ATRA)

      Daily Technical Chart for (NASDAQ: ATRA)


      Stay tuned for daily updates and more on (NASDAQ: ATRA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ATRA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATRA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ATRA and does not buy, sell, or trade any shares of ATRA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/